Insmed reported $765K in Interest Income for its fiscal quarter ending in September of 2024.





Interest Income Change Date
BioMarin Pharmaceutical USD 17.85M 973K Sep/2025
Cytokinetics USD 10.25M 2.75M Sep/2025
DBV Technologies USD -0.32 0.02 Sep/2024
Gilead Sciences USD 88M 15M Sep/2025
Heron Therapeutics USD 433K 277K Dec/2021
Insmed USD 765K 55K Sep/2024
Regeneron Pharmaceuticals USD 175.1M 300K Sep/2025
Sarepta Therapeutics USD 7.14M 3.05M Jun/2025
Ultragenyx Pharmaceutical USD 5.86M 69K Sep/2025
Vertex Pharmaceuticals USD 125.7M 3.3M Sep/2025